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OBJECTIVES We sought to establish the safety and efficacy of primary percutaneous transluminal coronary
angioplasty in patients with acute myocardial infarction (AMI) at two community hospitals
without on-site cardiac surgery.
BACKGROUND Though randomized studies indicate that primary angioplasty in AMI may result in superior
outcomes compared with fibrinolytic therapy, the performance of primary angioplasty at
hospitals without cardiac surgery is debated.
METHODS Three experienced operators performed 506 consecutive immediate coronary angiograms with
primary angioplasty when appropriate in patients with suspected AMI at two community
hospitals without cardiac surgery, following established rigorous program criteria.
RESULTS Clinical high risk predictors (Killip class 3 or 4, age $75 years, anterior AMI, out-of-hospital
ventricular fibrillation) and/or angiographic high risk predictors (left main or three-vessel
disease or ejection fraction ,45%) were present in 69.6%. Angioplasty was performed in
66.2%, with a median time from emergency department presentation to first angiogram of
94 min and a procedural success rate of 94.3%. The in-hospital mortality for the entire study
population was 5.3%. Of those without initial cardiogenic shock, the in-hospital mortality
was 3.0%. Of 300 patients who were discharged after primary angioplasty, only four died
within the first 6 months, with 97.7% follow-up. No patient died or needed emergent
aortocoronary bypass surgery because of new myocardial jeopardy caused by a complication of
the cardiac catheterization or angioplasty procedure.
CONCLUSIONS Immediate coronary angiography with primary angioplasty when appropriate in patients with
AMI can be performed safely and effectively in community hospitals without on-site cardiac
surgery when rigorous program criteria are established. (J Am Coll Cardiol 1999;33:
1257–65) © 1999 by the American College of Cardiology
Primary percutaneous transluminal coronary angioplasty has
been advocated for treatment of acute myocardial infarction
(AMI) for over 15 years (1,2). A meta-analysis of 10
multicenter randomized trials indicates that primary angio-
plasty in AMI lowers the rates of death, stroke, recurrent
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ischemia and reinfarction compared with fibrinolytic ther-
apy (3). In addition, for low risk patients with AMI, the
mortality of primary angioplasty can be very low (,0.5%),
and hospital costs can be decreased (4,5). Furthermore,
most AMI patients are not candidates for fibrinolytic
therapy, either because they have bleeding risks or shock, or
do not have diagnostic electrocardiograms (ECGs) (6–8).
These subgroups of patients may be at higher risk than
those eligible to receive fibrinolytic therapy. The invasive
approach can be applied to almost all of these patients at
capable centers. Moreover, primary angioplasty may be
more cost-effective than fibrinolytic therapy (9–13). Thus it
becomes increasingly important for both clinical and eco-
nomic reasons to address the question of whether this
interventional approach to the treatment of AMI can be
extended safely and effectively to a larger number of hospitals.
Most patients with AMI do not present to hospitals with
cardiac surgical capability. Yet approximately 840 hospitals
in the U.S. without cardiac surgery have cardiac catheter-
ization laboratories (14). Many of these laboratories are
staffed by experienced interventionalists who regularly per-
form elective intervention at surgical centers. Although the
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safety of primary angioplasty in hospitals without cardiac
surgery has not been well established, reports indicate that
the lack of in-house cardiac surgery may not adversely affect
outcomes in programs that are otherwise well qualified to
perform emergent angioplasty (15–22). We postulated that
the benefits of primary angioplasty could be provided safely
and effectively in hospitals without on-site cardiac surgery
by establishing rigorous standards for operators, staffing,
laboratories, equipment and case selection, and maintaining
ongoing outcomes analysis and case review. We report our
experience in performing immediate coronary angiography
with primary angioplasty when appropriate in 506 consec-
utive patients at two community hospitals without cardiac
surgery over a 74-month period.
METHODS
Operator, laboratory and institutional requirements. We
established the following standards for the performance of
primary angioplasty for operators, laboratories and institu-
tions at our two community hospitals without cardiac
surgery, approved by the ethics committees at both hospi-
tals:
1. The operators must be experienced interventionalists
who regularly perform elective intervention at a tertiary
surgical center.
2. The nursing and technical catheterization laboratory staff
must be experienced in handling acutely ill patients and
comfortable with interventional equipment. They must
have acquired experience in dedicated angioplasty labo-
ratories at a surgical center. They participate in a 24-h
365-day call schedule.
3. The catheterization laboratory itself must be well
equipped, with optimal imaging systems, resuscitative
equipment and intra-aortic balloon pump (IABP) sup-
port, and must be well stocked with a broad array of
interventional equipment.
4. The cardiac care unit nurses must be adept in hemody-
namic monitoring and IABP management.
5. The hospital administration must fully support the
program and enable the fulfillment of the above institu-
tional requirements.
6. There must be formalized written protocols in place for
immediate and efficient transfer of patients to the nearest
cardiac surgical facility.
7. Primary intervention must be performed routinely as the
treatment of choice around the clock for a large propor-
tion of patients with AMI, to ensure streamlined care
paths and increased case volumes.
8. Case selection for the performance of primary angio-
plasty must be rigorous. Criteria for the types of lesions
appropriate for primary angioplasty and for selection for
transfer for emergent aortocoronary bypass surgery are
listed under “Selection for angioplasty” and “Emergent
aortocoronary bypass surgery,” below.
9. There must be an ongoing program of outcomes analysis
and formalized periodic case review.
Study population. During the first three years of this
analysis (1991 to 1994), intervention was performed primar-
ily in patients with contraindications to fibrinolytics and in
those who were clinically at high risk (Killip class 3 or 4, age
.75 years, anterior AMI). Over the last three years of this
analysis (1994 to 1997), the invasive approach was used by
our group in 98% of all patients presenting with AMI.
Fibrinolytic therapy was used only in the rare instances
when the catheterization laboratory or the interventionalist
was not available or when the patient refused catheteriza-
tion.
The study population included patients with a clinical
impression of AMI: over 30 min of ischemic pain not
controlled by conventional medications (aspirin, nitroglyc-
erin, beta-adrenergic blocking agents and heparin, but not
fibrinolytic agents) or an ECG demonstrating $2.0 mV of
ST segment elevation in two or more contiguous leads.
There was no time cutoff if the clinical impression suggested
ongoing myocardial necrosis (ongoing chest pain and ST
deviation with preserved R waves in two or more infarct
leads). A small fraction of our patients (3.6%) presented
with 12 to 24 h of continuous chest pain with ST elevation
on ECG, and an even smaller fraction (2.2%) presented
with over 24 h of continuous pain and ST elevation. These
groups were included in this analysis. We did not include
patients who presented more than 12 h after onset of pain if
they were symptom-free on emergency department (ED)
arrival.
All patients with cardiogenic shock surviving the ED
were included. Also included were all patients with out-of-
hospital ventricular fibrillation who had successful cardio-
version in the field, regardless of acute mental status on
arrival. Patients with reversal of shock after angioplasty
generally had multivessel disease and were sent for urgent
aortocoronary bypass surgery before IABP removal. Not
included in this report are patients with ventricular septal
rupture or papillary muscle rupture, who were taken to the
catheterization laboratory for stabilization and IABP before
emergent transfer.
Techniques. Three experienced operators and two experi-
enced catheterization laboratory teams provided 24-h 365-
day coverage at two community hospitals without cardiac
surgery. Aspirin (325 mg chewed) was given in the ambu-
lance or immediately upon ED arrival along with heparin
Abbreviations and Acronyms
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(10 to 15,000 U), nitrates and intravenous beta-blockers as
indicated. The patient, after written informed consent, was
taken immediately to the catheterization laboratory, where
coronary angiography was performed with low osmolal ionic
contrast to reduce thrombotic complications (23). The
activated clotting time was kept above 350 s (between 200
and 300 s if stents or abciximab were used) with supple-
mental heparin as needed. The occluded infarct-related
artery (IRA) was identified and dilated; ventriculography
was deferred only in patients who were hemodynamically
unstable. For patients in shock, an IABP was inserted
before angiography via the opposite groin. The IABP was
also utilized after the procedure (via the same femoral access
site that was used for angiography) for some patients with
ongoing hemodynamic instability or high risk anatomy.
Nurses from the ED or the intensive care unit and respira-
tory therapists were called to the catheterization laboratory
to assist with the more critical patients as needed, especially
during nights and weekends, when only two of the cathe-
terization laboratory team were available on-call.
Selection for angioplasty. Angioplasty was not performed
if there was Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow (24) in the IRA in hemodynamically stable
asymptomatic patients, or if there was significant ($60%)
stenosis of an unprotected left main coronary artery up-
stream from an acute occlusion in the left coronary system
that might be disrupted by the angioplasty catheter. Angio-
plasty was also avoided in extremely long or angulated
infarct-related lesions with TIMI grade 3 flow, infarct-
related lesions with TIMI grade 3 flow in stable patients
with three-vessel disease (25,26), infarct-related lesions of
small or secondary vessels and lesions in other than the IRA
(unless they appeared to be flow-limiting in patients with
hemodynamic instability or ongoing symptoms).
Emergent aortocoronary bypass surgery. Patients were
transferred emergently for aortocoronary bypass surgery
after angioplasty of occluded vessels if they had high grade
residual left main or multivessel coronary disease with
clinical or hemodynamic instability. The transport time by
ambulance to the nearest surgical center is 45 min from one
hospital and 55 min from the other. Time intervals of as
short as 62 min from leaving the catheterization laboratory
to entering the operating room were documented.
Stents and abciximab usage. Stents and abciximab were
used only during the last several months of the data
collection period, when the results of angioplasty were
suboptimal.
Definitions. Angioplasty success was defined as TIMI
grade 3 flow and #50% residual stenosis (27). Reocclusion
was defined as greater than 90% restenosis with TIMI grade
0–1 flow. Reinfarction was defined as creatinine kinase MB
fraction reelevation above its previous nadir or chest pain
with ST segment reelevation and angiographic reocclusion.
Cardiogenic shock was defined as a sustained systolic
arterial pressure of ,90 mm Hg for over 30 min despite
fluids or requiring pressors, with a pulmonary wedge pres-
sure of .18 mm Hg or clinical evidence of elevated left
heart filling pressures, and signs of poor tissue perfusion
(oliguria, decreased mentation), without bradycardia, hypo-
volemia or other correctable causes of hypotension.
Data collection. Clinical data were collected at both hos-
pitals by a single experienced cardiology research nurse–
coordinator (author NSM) who had participated in previous
multicenter studies of AMI and whose reliability had been
verified in the site visits that were part of these studies. Data
were collected over a period of 74 months, from mid-1991
through mid-1997. A 239-field computerized relational
database was developed for data entry and analysis in 1993
and was completed for all procedures, retrospectively in
1991 and 1992 (187 cases), and prospectively since 1993
(319 cases). The potential for underreporting of adverse
outcomes was minimized by conducting a final review of all
records from all hospitals, including the surgical records, for
each patient several weeks after discharge. Six-month
follow-up by personal or telephone contact was attempted
in all patients who received primary angioplasty.
RESULTS
Five hundred six immediate coronary angiograms with
angioplasty standby were performed in 489 consecutive
patients with suspected AMI. Fifteen of these patients had
a second emergent procedure for reocclusion or recurrent
AMI on the same admission, and two of these had a third
emergent procedure for the same reasons. Clinical and
angiographic characteristics are shown in Table 1. Clinical
high risk predictors (Killip class 3 or 4, age $75 years,
anterior AMI, out-of-hospital ventricular fibrillation) (28)
were present at 272 procedures (53.7%) (Fig. 1). Angio-
graphic high risk predictors ($50% stenosis of the left main
coronary, $70% stenosis of all three major epicardial
coronary arteries or ejection fraction ,45%) were found in
246 (48.6%). Only 154 (30.4%) had none of these clinical or
angiographic high risk features. Three hundred ten (61.3%)
were considered poor candidates to receive fibrinolytic
therapy, because of age $80 years, the presence of bleeding
risks, shock or prior bypass surgery, the lack of ST segment
elevation on ECG or symptom duration over 6 h. Primary
angioplasty was performed during 335 of the 506 immediate
coronary angiograms (66.2%). It was not performed in 171,
or 33.8%, because: a) TIMI 3 flow was present in 25.9%
after the high dose heparin that was used; b) the lesion was
judged technically unsuitable in 6.1%, and c) the infarct
artery was unclear in 1.8%.
Outcomes. The median duration of chest pain before ED
arrival was 90 min. Angioplasty success was achieved in
94.3% of procedures (Table 2) at a median time from ED
arrival to first angiogram of 94 min (25th percentile 5
74 min, 75th percentile 5 134 min). A median of 15 more
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minutes elapsed before the first balloon inflation in those
undergoing angioplasty. The median time from pain onset
to reperfusion was 199 min. As seen in Table 2, the
mortality rate was relatively low for patients receiving
primary angioplasty, whether or not cardiogenic shock was
present.
In-hospital outcomes for the entire study population are
shown in Table 3. Rates of reocclusion and reinfarction
were relatively low. Stroke or transient ischemic attack
occurred in only two patients out of the entire population.
There were no occurrences of intracerebral bleeding. The
overall in-hospital mortality was 5.3%, including postoper-
ative mortality. In 56 patients who presented with cardio-
genic shock the mortality was 23.2%, and in patients
without shock it was 3%. Patients who presented with
out-of-hospital ventricular fibrillation treated with success-
ful countershock in the field had an in-hospital mortality of
11.4% (four of 35 patients). Of the 171 patients who had
primary angioplasty deferred because of initial TIMI grade
3 flow in the IRA, including 14 patients with shock,
reinfarction occurred in 1.8%, death in 3% and stroke in
none.
To more directly compare these outcomes with those of
other primary angioplasty and fibrinolytic studies, we ana-
lyzed the subgroup of 226 patients who presented with ST
segment elevation of at least 2 mV in two or more
contiguous leads or with left bundle branch block within 6 h
Table 1. Clinical and Angiographic Characteristics for 506
Immediate Coronary Angiography Procedures in Patients With
Suspected AMI
Characteristic
Mean Value 6 SD
or % of Procedures
Age (yr) 61 6 13
Age .70 25.3%
Female 28.9%
Prior AMI 21.3%
Prior bypass surgery 7.3%
Prior stroke or TIA 4.5%
Hypertension 48.8%
Diabetes 20.8%
Fibrinolytic eligible 38.7%
Killip class 3 13.4%
Cardiogenic shock* 11.3%
Out-of-hospital ventricular fibrillation† 6.9%
Diseased vessels ($70% stenosis)
0 5.5%
1 36.0%
2 28.1%
3 21.3%
Left main ($50% stenosis) 9.1%
Left ventricular ejection fraction (%) 49 6 16
*Sustained systolic arterial pressure of ,90 mm Hg despite fluids or requiring
pressors, pulmonary wedge pressure of .18 mm Hg, signs of poor tissue perfusion
(oliguria, decreased mentation) and absence of bradycardia, hypovolemia or other
correctable causes of hypotension. †Patients with documented ventricular fibrillation
occurring out of hospital who were successfully cardioverted in the field, regardless of
mental status on arrival. Data presented are mean value 6 SD or percent of
procedures.
AMI 5 acute myocardial infarction; TIA 5 transient cerebral ischemic attack.
Figure 1. Incidence of clinical and angiographic predictors of high risk. Clinical high risk predictors were present in 53.7% of 506
procedures (shown in middle layer); angiographic high risk predictors were present in 49.4% (lower layer). Both clinical and angiographic
high risk predictors were present in 33.5% (shown in black). Only 30.4% had neither clinical nor angiographic predictors of high risk
(upper layer). *Clinical high risk-Killip class 3–4, age $75 years, anterior infarction or prehospital ventricular fibrillation. †Angiographic
high risk: ejection fraction ,45% or left main or three-vessel disease.
Table 2. Outcomes of 335 Primary Angioplasty Procedures
Outcome
Mean Value 6 SD
or % of Procedures
Post-PTCA TIMI flow grade
0–1 4.8%
2 0.9%
3 94.3%
Post PTCA % stenosis 23 6 22
PTCA success* 94.3%
In-hospital mortality 6.6%
Presenting with cardiogenic shock
(n 5 44)
25.0%
Presenting without shock
(n 5 291)
3.8%
*#50% stenosis and TIMI grade 3 flow. Data presented are mean value 6 SD or
percent of procedures.
PTCA 5 percutaneous transluminal coronary angioplasty; TIMI 5 Thrombolysis
in Myocardial Infarction.
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of pain onset and without cardiogenic shock. Initial TIMI
grade 3 flow was present in 57 (25.2%). Primary angioplasty
was performed in 166 patients (73.5%), with success in 158
(95.2%). The in-hospital mortality was 3.1% (seven of 226)
for this group.
Complications. Table 4 lists the incidence of complica-
tions occurring in the catheterization laboratory. Thirty-six
procedures (7.1%) had at least one in-laboratory complica-
tion, 35 of which had no long-term sequelae. The single
in-laboratory death occurred in a patient in shock who
developed electromechanical dissociation at the time of
arrival at the catheterization laboratory, 32 min after ED
arrival, before attempted intervention. No patient died or
needed emergent aortocoronary bypass surgery because of
new myocardial jeopardy caused by a complication of the
procedure.
Bleeding after catheterization requiring transfusion oc-
curred in 48 patients (9.8%); 34 patients (6.9%) had
bleeding associated with the catheter access site, 3 of whom
developed retroperitoneal hematomas. The others had gas-
trointestinal, nasotracheal (after intubation) or genitouri-
nary bleeding. Over the last year of this study, the rate of
bleeding requiring transfusion fell to 5.9%.
Use of emergent aortocoronary bypass surgery. Twenty-
seven patients (5.3%) were transferred for and received
emergent aortocoronary bypass surgery within 12 h of
presentation because of initial shock (eight patients) or
critical multivessel disease (19 patients), none because of
new myocardial jeopardy caused by a procedural complica-
tion. Nineteen of the 27 were transferred with an open IRA
after successful primary angioplasty or spontaneous reper-
fusion. Of the other eight without reperfusion, seven had
anatomy judged unsuitable for angioplasty and one had
angioplasty that failed to open a totally occluded artery.
Twenty-five of the 27 survived. No complication occurred
during interhospital transfer.
Use of stents and abciximab. Seventeen stents were de-
ployed over the last few months of the study, all with
procedural success. Abciximab was used in 12 patients.
Six-month mortality. Six-month follow-up is available in
293 of 300 patients (97.7%) who were discharged after
primary angioplasty. Of this group of 293 patients, 98.6%
were alive at 6 months after discharge.
DISCUSSION
Rationale. The chief limitation to the widespread applica-
tion of primary angioplasty is the availability of qualified
hospitals and operators. Approximately 840 community
hospitals in the U.S. that have cardiac catheterization
laboratories do not have cardiac surgery (14). Many of these
hospitals are staffed by experienced and active intervention-
alists. In view of the potential advantages of primary
angioplasty, the question of whether the interventional
approach in the treatment of AMI can be extended safely
and effectively to these primary care hospitals must be
addressed.
We reasoned that the main surgical risk of elective
angioplasty, that of causing a patent vessel to close, need not
pertain to patients with AMI, where culprit vessels already
have occluded. We expected that the performance of im-
mediate coronary angiography in patients with AMI could
provide additional benefit through risk stratification and
triage (4). Further, we felt that our results could be opti-
mized if we committed to primary angioplasty as first-line
treatment; we reasoned that this would increase institutional
and operator experience and could streamline care paths,
shorten times to intervention and improve outcomes. Fi-
nally, we felt that this approach should not be limited to
Table 3. In-Hospital Outcomes in Patients Undergoing
Immediate Coronary Angiography
Outcome
% of Patients
Total
(n 5 489)
Initial
Cardiogenic
Shock
(n 5 56)
Without
Shock
(n 5 433)
Death 5.3% 23.2% 3.0%
Reinfarction* 2.5% 1.8% 2.5%
Reocclusion† 3.3% 1.8% 3.5%
Stroke or TIA
(none hemorrhagic)
0.4% 1.8% 0.2%
*Creatinine kinase, MB fraction, reelevation or chest pain with ST segment
reelevation and angiographic reocclusion. †Greater than 90% restenosis with Throm-
bolysis in Myocardial Infarction 0–1 flow. Data presented are percent of patients.
TIA 5 transient ischemic attack.
Table 4. Cardiac Catheterization Laboratory Complications in
506 Immediate Coronary Angiograms
Complication
% of
Patients
Any complication 7.1%
Asystole or heart block requiring pacemaker 3.9%
Ventricular fibrillation 2.7%
Aspiration 0
Respiratory arrest 0.4%
Pulmonary edema 0.8%
Anaphylaxis 0
Cardiogenic shock developing in lab 0
Acute renal failure 0.6%
Stroke or TIA 0
Vascular occlusion or pseudoaneurysm
(surgical repair)
0.8%
Coronary perforation 0.4%
Pericardial tamponade 0.2%
Emergency bypass surgery due to cath lab accident 0
Death 0.2%
Death due to cath lab complication 0
Data presented are percent of patients.
cath lab 5 cardiac catheterization laboratory; TIA 5 transient ischemic attack.
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those patients who fulfilled the usual criteria for inclusion in
fibrinolytic studies, since many high risk patients with AMI
and acute coronary occlusion do not present with diagnostic
ECGs or within 6 h of symptom onset, and since these
groups may be at higher risk (6–8).
The present study. This series represents the largest
single-group experience of primary angioplasty in hospitals
without on-site cardiac surgery ever reported to our knowl-
edge. The overall rates of successful angioplasty, reinfarc-
tion, stroke and death in our population compare very
favorably with the outcomes of large, high volume surgical
centers reported in the literature (Fig. 2) (4,5,25,26,29).
Moreover, our excellent low mortality rate in patients
having primary angioplasty is sustained at six months after
discharge.
Cardiogenic shock. The in-hospital mortality rate of
23.2% in 56 consecutive patients presenting in cardiogenic
shock is remarkable, being considerably lower than has been
reported (30,31). However, patients with cardiogenic shock
who are treated with prompt balloon counterpulsation and
early revascularization in some studies have mortality rates
that are similarly low (32–36). The low mortality in our
series might be explained by several factors: 1. immediate
balloon counterpulsation and effective angioplasty revascu-
larization may improve outcomes; 2. the short duration of
symptoms before ED arrival in this series (median 78 min)
should increase the likelihood of salvageable myocardium,
and 3. selection bias may in part account for the improved
outcomes reported in patients with shock who are treated
with intervention (37). In our series, however, all patients
who presented with shock and who survived the ED are
included. The management of cardiogenic shock at com-
munity hospitals is being addressed by ongoing studies. Our
approach may improve the effectiveness of the initial treat-
ment of the shock patient at the point of first presentation,
and can avoid the delays and risks that are associated with
the interhospital transfer of unsupported patients in shock.
Angioplasty rate. The rate of performance of primary
angioplasty of 66.2% in all patients taken to the catheter-
ization laboratory and 73.5% in patients with ST segment
elevation is lower than that in other primary angioplasty
studies (25,26). This is because of rigorous case selection for
intervention; to avoid creating a surgical emergency at
nonsurgical hospitals by causing acute closure of an already
open IRA, primary angioplasty of vessels with initial TIMI
grade 3 flow was withheld in stable, pain-free patients. This
proved to be a very safe approach. A large proportion of this
group with initial TIMI grade 3 flow had subsequent
revascularization at a tertiary hospital. Another reason for
the lower angioplasty rate is that immediate coronary
angiography with primary angioplasty standby was per-
formed on a broader population often not included in other
studies, including patients presenting over 12 h after pain
onset and patients without diagnostic ECGs. In this pop-
ulation, where immediate angiography was used for diag-
nosis and triage as well as an antecedent to primary
angioplasty, we expected and found a higher percentage
with TIMI grade 3 flow.
Limitations. The patients in this series were not random-
ized. Although our experience demonstrates outcomes that
can be achieved at community hospitals without cardiac
surgery, these data provide no indication of whether alter-
native treatments (using fibrinolytics when possible) might
have led to similar outcomes. The interventional approach
in AMI, however, can be applied to a much broader
population than fibrinolytic therapy. Any randomized com-
parison with fibrinolytic therapy would exclude a very
important large and high risk population (6–8) of fibrino-
lytic ineligible patients. One value of this study is that it
includes, and demonstrates excellent outcomes in, patient
Figure 2. Comparison of the outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) in the 231 patients in our
series who had acute myocardial infarction with ST segment elevation but without cardiogenic shock with a similar population of 245
patients undergoing primary PTCA in the Primary Angioplasty Registry (25), which required ST segment elevation and excluded patients
with shock. The median times from emergency department (ED) arrival to reperfusion and the rates of PTCA success, reinfarction, stroke
or transient ischemic attack (TIA), and in-hospital mortality were similar in the two groups. Black bars: Exeter and Portsmouth primary
PTCA patients presenting with ST elevation without shock (n 5 231). White bars: Primary Angioplasty Registry PTCA patients (n 5
245).
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groups often excluded from randomized studies of fibrino-
lytic therapy.
Another limitation is that these results may not be
replicable at other community hospitals. The outcomes of
primary angioplasty for AMI are very much dependent on
operator expertise and institutional commitment. We be-
lieve, however, that results similar to ours can be achieved by
cardiologists and institutions that establish programs which
adopt rigorous standards such as those we propose (see
Methods). Preliminary data from the Primary Angioplasty
in Myocardial Infarction—No Surgery on Site Registry
supports this view (21,22).
A further limitation is that these data were collected
retrospectively on the first 187 patients, which could have
resulted in an inadvertent selection bias. The decision on
which patients to include retrospectively in this series was
made by the cardiology research nurse–coordinator, who
independently reviewed the catheterization laboratory logs
and the hospital charts for over 300 urgent procedures to
find these 187 patients with AMI. Decisions were made by
reviewing ED notes, admission and progress notes and
ECGs, specifically without regard to patient outcomes.
The study is also limited by the fact that stents or
abciximab were not used in 95.8% of procedures. Recent
studies of these agents in patients undergoing high risk or
primary angioplasty suggest their potential to improve
outcomes (38–42). Thus these two new modalities may
further improve the safety and efficacy of primary angio-
plasty and could provide an extra measure of safety at
hospitals without cardiac surgery.
Finally, there is no core laboratory analysis of the cinean-
giograms. The diameter of stenoses and the TIMI flow
grades were visually estimated. Thus the self-reported rates
of angioplasty success might be overly optimistic, and might
be expected to decrease somewhat after core laboratory
quantitative coronary angiography analysis (43). It should be
noted, however, that the visual estimate of TIMI flow grade
and lesion diameter is the usual basis on which interven-
tional decisions are made in the catheterization laboratory.
Moreover, visual assessment of the immediate change in
percent stenosis after angioplasty has been shown to be
superior to quantitative coronary angiography in predicting
symptom-free survival at 1 year (44).
Conclusions. These outcomes indicate that immediate
coronary angiography with primary angioplasty when ap-
propriate in patients with acute myocardial infarction can be
performed safely and effectively at community hospitals
without cardiac surgery, with excellent outcomes in a large,
high risk population. By establishing rigorous standards for
operators, staffing, laboratories, equipment and case selec-
tion, and maintaining ongoing outcomes analysis and case
review, primary angioplasty can be performed consistently,
rapidly and with success and complication rates similar to
those of large experienced surgical centers. Moreover, early
knowledge of coronary anatomy enabled informed thera-
peutic decisions, including early selection of highest risk
patients for aortocoronary bypass surgery and early recog-
nition of a large subgroup of patients who had patent vessels
after aspirin and high dose heparin, whose initial manage-
ment could be more conservative.
These results should not be understood to mean that
infarct angioplasty can or should be done at every hospital
with cardiac catheterization facilities. But this report does
suggest that the lack of cardiac surgery backup, per se, need
not limit the application, safety or efficacy of this valuable
modality in the treatment of a broader spectrum of patients
with acute myocardial infarction. Multicenter studies of
primary angioplasty at hospitals without cardiac surgery are
needed to help assess the feasibility, safety and efficacy of
this approach on a large scale nationwide. At least two such
studies are now ongoing (21).
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